Inventor
ROZEMA DAVID B
US72 patents
⚠️ This page may combine multiple inventors who share the name “ROZEMA DAVID B”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MIRUS BIO CORP
12 patentsUS7138382B2Nov 21, 2006
Compositions and methods for drug delivery using pH sensitive molecules
MIRUS BIO CORP83 citations98
US7098032B2Aug 29, 2006
Compositions and methods for drug delivery using pH sensitive molecules
MIRUS BIO CORP114 citations98
US7033607B2Apr 25, 2006
pH-titratable polyampholytes for delivering polyions to a cell
MIRUS BIO CORP34 citations93
US7348453B2Mar 25, 2008
Labile linkage for compound delivery to a cell
MIRUS BIO CORP24 citations92
US7098030B2Aug 29, 2006
Polyampholytes for delivering polyions to a cell
MIRUS BIO CORP25 citations92
US7087770B2Aug 8, 2006
Compound containing a labile disulfide bond
MIRUS BIO CORP20 citations92
US7019113B2Mar 28, 2006
Reversible modification of membrane interaction
MIRUS BIO CORP38 citations92
US6867196B1Mar 15, 2005
Process for delivering nucleic acids to cardiac tissue
MIRUS BIO CORP30 citations90
US7208314B2Apr 24, 2007
Compositions and methods for drug delivery using pH sensitive molecules
MIRUS BIO CORP16 citations84
US6897068B2May 24, 2005
Polynucleotide complex delivery
MIRUS BIO CORP18 citations84
US6936729B2Aug 30, 2005
Compound containing a labile disulfide bond
MIRUS BIO CORP11 citations74
US7094605B2Aug 22, 2006
Formation of polyampholytes in the presence of a polyion
MIRUS BIO CORP6 citations73
ARROWHEAD PHARMACEUTICALS INC
10 patentsUS10130651B2Nov 20, 2018
RNAi Therapy for Hepatitis B Virus Infection
ARROWHEAD PHARMACEUTICALS INC22 citations94
US10246709B2Apr 2, 2019
Targeting ligands for therapeutic compounds
ARROWHEAD PHARMACEUTICALS INC10 citations83
US10780108B2Sep 22, 2020
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC5 citations82
US10662427B2May 26, 2020
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC6 citations82
US9932586B2Apr 3, 2018
Compositions and methods for inhibiting gene expression of LPA
ARROWHEAD PHARMACEUTICALS INC9 citations82
US10806750B2Oct 20, 2020
RNAi therapy for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC3 citations73
US11590156B2Feb 28, 2023
RNAi agents for hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US11517584B2Dec 6, 2022
RNAi agents for Hepatitis B virus infection
ARROWHEAD PHARMACEUTICALS INC2 citations72
US10927373B2Feb 23, 2021
Compositions and methods for inhibiting gene expression of Hif2alpha
ARROWHEAD PHARMACEUTICALS INC2 citations71
US10316316B2Jun 11, 2019
Compositions for targeted delivery of siRNA
ARROWHEAD PHARMACEUTICALS INC1 citations69
ROZEMA DAVID B
8 patentsUS8313772B2Nov 20, 2012
Compositions for targeted delivery of siRNA
ROZEMA DAVID B159 citations99
US8541548B2Sep 24, 2013
Compounds and methods for reversible modification of biologically active molecules
ROZEMA DAVID B85 citations98
US8501930B2Aug 6, 2013
Peptide-based in vivo siRNA delivery system
ROZEMA DAVID B180 citations98
US8137695B2Mar 20, 2012
Polyconjugates for in vivo delivery of polynucleotides
ROZEMA DAVID B138 citations98
US8658211B2Feb 25, 2014
Polyconjugates for in vivo delivery of polynucleotides
ROZEMA DAVID B71 citations97
US8426554B2Apr 23, 2013
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
ROZEMA DAVID B47 citations97
US8802773B2Aug 12, 2014
In vivo polynucleotide delivery conjugates having enzyme sensitive linkages
ROZEMA DAVID B12 citations92
US9011919B2Apr 21, 2015
Compositions for targeted delivery of siRNA
ROZEMA DAVID B7 citations82
ARROWHEAD MADISON INC
6 patentsUS9796756B2Oct 24, 2017
Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA
ARROWHEAD MADISON INC24 citations93
US9345775B2May 24, 2016
Compositions for targeted delivery of siRNA
ARROWHEAD MADISON INC5 citations84
US9976141B2May 22, 2018
Compositions and methods for inhibiting gene expression of Hif2alpha
ARROWHEAD MADISON INC5 citations82
US9107957B2Aug 18, 2015
Peptide-based in vivo siRNA delivery system
ARROWHEAD MADISON INC5 citations81
US9487556B2Nov 8, 2016
Polyconjugates for delivery of RNAi triggers to tumor cells in vivo
ARROWHEAD MADISON INC6 citations80
US9526796B2Dec 27, 2016
Peptide-based in vivo siRNA delivery system
ARROWHEAD MADISON INC3 citations73
MIRUS CORP
5 patentsUS6919091B2Jul 19, 2005
Compositions and methods for drug delivery using pH sensitive molecules
MIRUS CORP39 citations96
US6740643B2May 25, 2004
Compositions and methods for drug delivery using amphiphile binding molecules
MIRUS CORP68 citations96
US6630351B1Oct 7, 2003
Compositions and methods for drug delivery using pH sensitive molecules
MIRUS CORP61 citations96
US6379966B2Apr 30, 2002
Intravascular delivery of non-viral nucleic acid
MIRUS CORP71 citations96
US6627616B2Sep 30, 2003
Intravascular delivery of non-viral nucleic acid
MIRUS CORP46 citations93
ROCHE MADISON INC
3 patentsUS7482160B2Jan 27, 2009
Process of making a compound by forming a polymer from a template drug
ROCHE MADISON INC11 citations92
US7816337B2Oct 19, 2010
Reversible attachment of a membrane active polymer to a polynucleotide
ROCHE MADISON INC12 citations83
US7682626B2Mar 23, 2010
Polyvinylethers for delivery of polynucleotides to mammalian cells
ROCHE MADISON INC10 citations83
nanoSUR LLC
3 patentsUS11174480B2Nov 16, 2021
Post-transcriptionally chemically modified double strand RNAs
nanoSUR LLC1 citations70
US10640769B2May 5, 2020
Post-transcriptionally chemically modified double strand RNAs
nanoSUR LLC2 citations70
US10131911B2Nov 20, 2018
Post-transcriptionally chemically modified double strand RNAs
nanoSUR LLC4 citations70
WISCONSIN ALUMNI RES FOUND
1 patentMIRNS BIO CORP
1 patentHADWIGER PHILIPP
1 patentShowing the top 50 of 72 patents by PatentIndex Score.